We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Argenta Announces Drug Discovery Agreement with Cellzome
News

Argenta Announces Drug Discovery Agreement with Cellzome

Argenta Announces Drug Discovery Agreement with Cellzome
News

Argenta Announces Drug Discovery Agreement with Cellzome

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Argenta Announces Drug Discovery Agreement with Cellzome"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Argenta Discovery has announced that it has entered into drug discovery collaboration with Cellzome, Inc.

Under the terms of the agreement Argenta will apply its integrated medicinal chemistry, assay development and screening capabilities and collaborate with Cellzome’s scientists in the search for disease therapies.

The deal also provides Cellzome with access to Argenta's other integrated scientific disciplines including ADME/PK.

Dr Chris Ashton, Argenta's CEO, said, “We are delighted that one of Europe's leading biotechnology companies has chosen to work with Argenta.”

He adds, “This new agreement illustrates Argenta’s excellence in providing fully integrated collaborative drug discovery solutions.”

Further he said, “Last year our contract research business revenue grew by over 25% and we have had an excellent start to the new financial year: this being the third collaborative agreement we have signed in the last five months.”

Tim Edwards, CEO of Cellzome, added, “We chose to work with Argenta because of the experience of the Argenta team; they can provide us with high quality, reproducible results.”

He adds, "This collaboration will further extend and compliment our own drug discovery unit and will help us move our projects forwards into the clinic."

Advertisement